Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Idea to Innovation

McMaster University

$348,440.00

Market translation of a rapid aptamer-based COVID-19 saliva test

EF 2022-23

Résumé
The proposed project is focused on commercializing a rapid COVID-19 saliva test prototype developed at McMaster University and licensed by the Canadian company, Zentek. In this test, saliva is deposited on a chip that is inserted into an electrical reader for rapid, 10 minute, COVID-19 testing. This is a reliable rapid test with no discomfort to the user that is tested with more than 70 patients, demonstrating sensitivity of >80%, specificity of 100%, and concordance value of 92% (total agreement of the test result with the gold standard PCR test). Despite the availability of a wide range of COVID-19 tests, there is no regulatory-approved rapid saliva test due to the deterioration of test performance in saliva. Our test combines two technologies for high reliability testing in saliva: dimeric aptamers and electrochemical readout. Aptamers are DNA molecules selected from a large DNA library using in vitro selection to specifically bind target analytes, in this case the spike protein of SARS-CoV-2. Because dimeric aptamers bind the target spike protein from two locations, they result in high affinity binding. Additionally, dimeric aptamers can be rapidly generated in response to new viral variants. We use an ultrasensitive readout method, electrochemical impedance spectroscopy, for translating this target binding to an electrochemical signal. We have developed the test prototype using commercially-available screen printed electrodes coupled to a USB-sized phone dongle as a signal reader to enable rapid technology translation.Technical issues related to scalable fabrication, stability, detection of emerging viral variants, sample collection, and simple assay operation will be addressed in this project. The development of this technology in Canada will create more than 100 direct jobs at Zentek and will contribute to keeping the economy open while maintaining low infection rates. Zentek intends to develop this technology for detecting other infectious diseases, further growing job creation and contribution to the health and economic wellbeing of Canadians.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
571001-2022
Name nom
Soleymani, Leyla L
Department département
Engineering Physics
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
348440
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:1;2
Partie
2
Nb partie
2
Application title
Market translation of a rapid aptamer-based COVID-19 saliva test
Application summary
The proposed project is focused on commercializing a rapid COVID-19 saliva test prototype developed at McMaster University and licensed by the Canadian company, Zentek. In this test, saliva is deposited on a chip that is inserted into an electrical reader for rapid, 10 minute, COVID-19 testing. This is a reliable rapid test with no discomfort to the user that is tested with more than 70 patients, demonstrating sensitivity of >80%, specificity of 100%, and concordance value of 92% (total agreement of the test result with the gold standard PCR test). Despite the availability of a wide range of COVID-19 tests, there is no regulatory-approved rapid saliva test due to the deterioration of test performance in saliva. Our test combines two technologies for high reliability testing in saliva: dimeric aptamers and electrochemical readout. Aptamers are DNA molecules selected from a large DNA library using in vitro selection to specifically bind target analytes, in this case the spike protein of SARS-CoV-2. Because dimeric aptamers bind the target spike protein from two locations, they result in high affinity binding. Additionally, dimeric aptamers can be rapidly generated in response to new viral variants. We use an ultrasensitive readout method, electrochemical impedance spectroscopy, for translating this target binding to an electrochemical signal. We have developed the test prototype using commercially-available screen printed electrodes coupled to a USB-sized phone dongle as a signal reader to enable rapid technology translation.Technical issues related to scalable fabrication, stability, detection of emerging viral variants, sample collection, and simple assay operation will be addressed in this project. The development of this technology in Canada will create more than 100 direct jobs at Zentek and will contribute to keeping the economy open while maintaining low infection rates. Zentek intends to develop this technology for detecting other infectious diseases, further growing job creation and contribution to the health and economic wellbeing of Canadians.